Click here for Korean translation
http://cafe.naver.com/ybmt
Shares of Genentech are getting a big boost after some positive results for one of its drugs. Its breast cancer treatment, Herceptin, showed promise in a trial of women with early stage cancer. The drug is already approved for treatment of the sickest breast cancer patients but the new results have raised hopes that it will be cleared for wider use. Genentech shares have performed well over the last year, thanks in part to good results from its colon cancer drug.
All Comments